Navigation Links
Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
Date:12/7/2007

CARLSBAD, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that its President and Chief Executive Officer, Barry D. Quart, PharmD, will participate in the "In Search of the Next HIV Treatment" panel discussion at the RBC Capital Markets 2007 Healthcare Conference on Wednesday, December 12, 2007 at 1:30 p.m. (ET) at the Westin Times Square Hotel in New York City. A live audio webcast of the presentation and panel discussion will be accessible through Ardea's Investor Center web site at http://www.ardeabio.com.

Event: RBC Capital Markets Healthcare Conference

Presenter: Barry D. Quart, PharmD, President and Chief Executive Officer,

Ardea Biosciences

Date: Wednesday, December 12, 2007

Time: 1:30 p.m. Eastern Time

Location: The Westin Times Square, New York City

Webcast: http://www.ardeabio.com

About Ardea Biosciences, Inc.

Ardea Biosciences is focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to have active development programs with four new chemical entities (NCEs) in the clinic for three distinct indications by the end of 2007, with an additional one-to-two indications in inflammatory diseases planned for the first half of 2008.

Ardea's most advanced clinical development programs include: RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which is expected to enter a Phase 2a clinical trial in the fourth quarter of 2007; RDEA119,
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., NOVATO, Calif., Nov. 30 /PRNewswire-FirstCall/ ...nnounced today that the Food and Drug Administrati...,4-diaminopyridine (3,4-DAP), amifampridine phosph... Myasthenic Syndrome (LEMS). 3,4-DAP has previous...lso, in October 2009, the Committee for Medicinal ...
(Date:11/30/2009)... , SHANGHAI, Nov. 30 /PRNewswire-Asia/ -...eutical, biotechnology, and medical-device researc...ons in China and the United States,announced that...ast 50 China,2009 list for the fifth consecutive y...mpanies in China,s technology, media, and telecomm...
(Date:11/28/2009)... The Vanuatu National Advisory Co...nd National Communication (SNC) Project in collabo...d CLIMsystems Ltd. of New Zealand have generated p...ts that will form the background for the country&r...rk Convention on Climate Change (UNFCCC). , ...
(Date:11/26/2009)...ST LAFAYETTE, Ind. - A new generation of ultrasmal...ng tiny structures called semiconducting nanowires...searchers at IBM, Purdue University and the Univer...hers have learned how to create nanowires with lay...d at the atomic level, which is a critical require...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3
...., Feb. 17 Sequella, Inc., a clinical-stage bioph...ic potential, today announced the receipt of a Sma...nt from the National Institute of Allergy and Infe...alth (NIH), to fund further preclinical developmen...piperidine drug compound, SQ609. , , The SBIR gr...
...nexpected happens, www.WhatWillYourPlanBe.com offe...er, financial planning and sexual health , , MONT...eal world" expecting that life will go according t...s, finances and relationships. Unfortunately, the... looming problem especially in today,s challenging...
...F, Germany, February 17 , - Sales Grow by 10.7%...proves by 36.6% From EUR1.34 Euro to, EUR1.83...9.5%, - CEO Dr. Axel Herberg: "Following the re...rs itself well equipped to meet the global challen...ntial sales growth of 6% to 7% in, the core b...
Other Biology Technology:Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609 2Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609 3Helping Young Women Succeed in Today's Unpredictable World 2Helping Young Women Succeed in Today's Unpredictable World 3Helping Young Women Succeed in Today's Unpredictable World 4Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 2Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 3Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 4
(Date:11/26/2009)...sive antlers, red deer have been caught in the hun... are much more than decorative. They are lethal we...n Currey, from The University of York, UK, has bee...or over half a century and has become fascinated b...ng-standing collaboration with Tomas Landete-Casti...
(Date:11/26/2009)...tant Staphylococcus Aureus ) and other drug-resis...rature plasma prototype devices have been develope...cidal cocktails. , Two prototype devices have be...althy skin (e.g. hands and feet) in hospitals and ...eat; and another to shoot bacteria-killing agents ...
(Date:11/25/2009)...ad of the Cell Death Research Laboratory in the Un...n awarded the prestigious Johnson & Johnson Focuse...se of brain cell damage in Parkinson,s disease. Th...in support of innovation and excellence in science...earlier this month at an event at the Hyatt Regenc...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2First Site in CalRHIOs Statewide Health Information Exchange Goes Live in Orange County 59493 1First Site in CalRHIOs Statewide Health Information Exchange Goes Live in Orange County 59493 2First Site in CalRHIOs Statewide Health Information Exchange Goes Live in Orange County 59493 3Press Ganey Partners With Health Management Associates 5494 1Press Ganey Partners With Health Management Associates 5494 2NIMBioS hosts 200 undergraduates at national research conference 10362 1
...kin cancer, researchers at the Huntsman Cancer Ins...to inhibit a mutant gene found in up to 30 percent...his gene are important in cell signaling, or commu...s an "oncogene" or cancer-causing gene that has be...ancreas, colon and lung, as well as thyroid cancer...
...on storage molecule in the cell can serve as an ad...ne therapy may use a technique in which non-invasi...ck this molecule. The results of this research, co...titute,s Biological Regulation Department, were pu...n, together with Dr. Batya Cohen of the Institute,...
...icine researchers have discovered how new neurons ... regions of the brain where they can replace old a...ell therapies can be specifically targeted to brai...r by stroke. , Associate Professor Qun-Yong Zhou a...nt of Pharmacology have identified a protein that ...
Other Biology News:Scientists inhibit cancer gene 2Novel live reporting system to track cells 2Researchers discover stem cell 'guide' that may be key for targeting neural stem cell treatments 2
Feline IL-12 / IL-23 p40, Unconjugated from R&D Systems
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100* from Molecular Probes (Invitrogen)
dithiothreitol (DTT) from Molecular Probes (Invitrogen)
.... • The major histocompatibility complex is t.... There is great interest in the structure of MHC ...ng molecules. Many immunology labs are now faced w...ic techniques in order to study these molecules an...
Biology Products: